about
Visceral Leishmaniasis on the Indian Subcontinent: Modelling the Dynamic Relationship between Vector Control Schemes and Vector Life CyclesOf cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination.Phlebotomine sandfly ecology on the Indian subcontinent: does village vegetation play a role in sandfly distribution in Bihar, India?A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies.Glycoinositolphospholipids from Leishmania braziliensis and L. infantum: modulation of innate immune system and variations in carbohydrate structureDDT-based indoor residual spraying suboptimal for visceral leishmaniasis elimination in IndiaApplication of RFLP-PCR-Based Identification for Sand Fly Surveillance in an Area Endemic for Kala-Azar in Mymensingh, BangladeshAsymptomatic leishmaniasis in kala-azar endemic areas of Malda district, West Bengal, India.Developments in diagnosis and antileishmanial drugs.Two biochemically distinct lipophosphoglycans from Leishmania braziliensis and Leishmania infantum trigger different innate immune responses in murine macrophagesChronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities?Particle induced X-ray emission study of blood samples of Indian Kala-azar patients.Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism.A case report of co-infection of Melioidosis and cutaneous Leishmaniasis.Development and Assessment of Loop-Mediated Isothermal Amplification (LAMP) Assay for the Diagnosis of Human Visceral Leishmaniasis in Iran.Bionomics of Phlebotomus argentipes in villages in Bihar, India with insights into efficacy of IRS-based control measures.Leishmania donovani Activates Hypoxia Inducible Factor-1α and miR-210 for Survival in Macrophages by Downregulation of NF-κB Mediated Pro-inflammatory Immune Response.
P2860
Q28553588-1AF09E41-89C8-4E5A-A80F-95E84993FD83Q33531749-B650239A-E6BC-4786-AFA0-7E9244C20303Q33625550-C9DAEA46-F157-4D0F-A459-5FB6B3E8BBB6Q33769341-BD5B35F9-25F7-4109-A88A-9F65C1C225D6Q34043521-ADBDAFC2-F6AE-4F48-8BC5-CE29C83F6326Q34156124-9913D6B9-00DE-4D81-B974-482943732015Q34184759-55E09D09-80E7-4DB1-8F3C-D3576CA8F925Q35865636-837FBB83-551B-4608-95A3-B52B0AABD882Q36014682-9974945F-B056-4F1F-882C-1576A068E974Q36277146-1199EA44-B5E4-4DA3-A29A-79170DC5A04FQ36355665-BF950B66-CA59-4D6A-94BC-2882C29CD303Q36710445-A898AE06-2572-4A9B-94E6-5CE3BEDFEC92Q37377483-8F97C98C-0491-40DD-84F1-3F3F70252BAFQ37712177-E7066C7F-F1B1-4F8B-836F-37AABDF68D89Q38895807-0F3FE456-3AB7-4118-AE50-2E4C4BF7F506Q39599468-1298F9FC-E2BF-4CD1-9B5D-C24882BDAE70Q39942052-991BCEA2-7F38-40FD-9D3D-3D0CCF9A026FQ40045144-762E2192-FE98-42ED-A78C-C5A9FBACD8B2Q40171529-0892CD5C-4CF0-4C65-8286-1CB3E6C5EC9BQ48259967-7802845B-A8BF-499D-A2E0-C9437AA07EE0Q54250480-5D7D18B4-3733-4679-B353-AF27543504A3
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Visceral leishmaniasis (kala-azar): challenges ahead.
@ast
Visceral leishmaniasis (kala-azar): challenges ahead.
@en
type
label
Visceral leishmaniasis (kala-azar): challenges ahead.
@ast
Visceral leishmaniasis (kala-azar): challenges ahead.
@en
prefLabel
Visceral leishmaniasis (kala-azar): challenges ahead.
@ast
Visceral leishmaniasis (kala-azar): challenges ahead.
@en
P1476
Visceral leishmaniasis (kala-azar): challenges ahead.
@en
P2093
P304
P407
P50
P577
2006-03-01T00:00:00Z